Evidence map›Paper›PMID 25850966›Full record

ArticlePharmacogenetics and genomics2015

Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders.

Alex J Brewer, David A Nielsen, Catherine J Spellicy, Sara C Hamon, Justin Gingrich, Daisy G Y Thompson-Lake, Ellen M Nielsen, James J Mahoney, Thomas R Kosten, Thomas F Newton and 1 more

Abstract read
In one paragraph

Article in Pharmacogenetics and genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. PGx-BasedCurrent neuropharmacology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Alex J BreweraDepartment of Pharmacology bMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine cMichael E. DeBakey Veterans Affairs Medical Center, Houston, Texas dLaboratory of Statistical Genetics, The Rockefeller University, New York, New York, USA.
David A Nielsen
Catherine J Spellicy
Sara C Hamon
Justin Gingrich
Daisy G Y Thompson-Lake
Ellen M Nielsen
James J Mahoney
Thomas R Kosten
Thomas F Newton
Richard De La Garza
Baylor College of Medicine · USStatistical Service · CY

Funding

Tiagabine and Disulfiram for Cocaine DependenceP50DA018197 · NIDA · YALE UNIVERSITY · PI KOSTEN, THOMAS RICHARD · 2004 to 2013
$12.6M
Rivastigmine and Huperzine A as Potential Treatments for Cocaine AddictionR01DA023624 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI DE LA GARZA, RICHARD · 2009 to 2012
$2.0M
Innovative Multidisciplinary Education: The Statistical Genetics of AddictionR25DA026120 · NIDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHANG, SHINE, SHETE, SANJAY · 2010 to 2014
$1.5M
NIDA NIH HHS DA023624NIDA NIH HHS DA026120NIDA NIH HHS P50 DA018197NIDA NIH HHS R01 DA023624NIDA NIH HHS R25 DA026120
6 · The paper itself

Abstract

objectiveThe aim of this study was to identify gene variants of DAT1 (SLC6A3) that modulate subjective responses to acute cocaine exposure.

methodsNon-treatment-seeking volunteers (n=66) with cocaine use disorders received a single bolus infusion of saline and cocaine (40 mg, intravenous) in a randomized order. Subjective effects were assessed with visual analog scales administered before (-15 min) and up to 20 min after infusion. Ratings of subjective effects were normalized to baseline, and saline infusion values were subtracted. Data were analyzed using repeated measures analysis of variance. DNA from the participants was genotyped for the DAT1 intron 8 (rs3836790) and 3'-untranslated region (rs28363170) variable number of tandem repeats.

resultsParticipants were mostly male (∼80%) and African American (∼70%). No differences were found among drug use variables between groups for either polymorphism. Carriers of the 9-allele of the DAT1 3'-untranslated region (9,9 and 9,10) exhibited greater responses to cocaine for 'high', 'any drug effect', 'anxious', and 'stimulated' (all P-values<0.001) compared with individuals homozygous for the 10-allele. For the intron 8 polymorphism, individuals homozygous for the 6-allele exhibited greater responses for 'anxious' compared with carriers of the 5-allele (P<0.001). Individuals possessing the genotype pattern of 10,10 and at least one 5-allele reported lower responses to 'good effects', 'bad effects', 'depressed', and 'anxious' (all P-values<0.01).

conclusionThe data presented here show for the first time support for the hypothesis that genetic differences in DAT1 contribute to the variation in subjective responses to cocaine among participants with cocaine use disorders.

Indexed as

3' Untranslated RegionsAdolescentAdultAllelesBlack or African AmericanBlood PressureCocaineCocaine-Related DisordersDopamine Plasma Membrane Transport ProteinsFemaleGenotypeHeart RateHumansIntronsMaleMiddle Aged3' Untranslated RegionsCocaineDopamine Plasma Membrane Transport ProteinsSLC6A3 protein, human

Identifiers

PMID25850966
PMCPMC4414865
OpenAlexW2155659014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.